<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278718</url>
  </required_header>
  <id_info>
    <org_study_id>MW2012-01-01</org_study_id>
    <nct_id>NCT02278718</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care</brief_title>
  <official_title>A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediWound Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediWound Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a two-arms study intending to demonstrate superiority of NexoBrid&#xD;
      treatment over SOC in children with thermal burns. The study objective is to evaluate the&#xD;
      safety and clinical benefit of NexoBrid in hospitalized children (0-17 years) with deep&#xD;
      partial and/or full thickness thermal burns of 1-30% TBSA and to compare NexoBrid to standard&#xD;
      of care (SOC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 160 patients will be randomized into NexoBrid and SOC treatment (80 patients per&#xD;
      arm).&#xD;
&#xD;
      Age distribution will be managed as follows:&#xD;
&#xD;
        -  45 patients 0-23 months old&#xD;
&#xD;
        -  45 patients 24 months-3 years old&#xD;
&#xD;
        -  30 patients 4-11 years old&#xD;
&#xD;
        -  20 patients 12-17 years old The remaining 20 patients will be enrolled to any of the&#xD;
           above groups, per their age during enrollment.&#xD;
&#xD;
      The study will be conducted in three stages. In Stage I, at least 24 children age 4-18 years,&#xD;
      hospitalized in burn units, with deep partial thickness burns ranging from 1%-30% TBSA, and&#xD;
      who meet the entrance criteria, will be enrolled. Upon completion of stage I, a safety&#xD;
      analysis will be performed on safety parameters and the results will be evaluated by a Data&#xD;
      Safety Monitoring Board (DSMB) as defined in the agreed charter. If the DSMB does not have&#xD;
      any safety concerns, Stage II will commence, this time enrolling at least 26 additional&#xD;
      children aged of 1-18 years according to the study procedures. A DSMB will be convened to&#xD;
      assess the safety data of the first 50 patients enrolled at stages 1 &amp; 2. If the DSMB has not&#xD;
      found any safety concerns, stage III will commence in which patients from the age of birth to&#xD;
      18 years will be included (stage III will include 110 remaining patients required to reach a&#xD;
      total of 160 patients).&#xD;
&#xD;
      Following the enrollment of a subject to the study and prior to randomization, physicians&#xD;
      will define one or more Target Wounds (TWs) per subject according to TWs definition. All&#xD;
      subjects' DPT and FT burns that fit the specified criteria are intended to receive study&#xD;
      treatment per randomized study arm and therefore, must be designated as TWs.&#xD;
&#xD;
      Prior to eschar removal treatment with NexoBrid or SOC subjects will be medicated with&#xD;
      appropriate analgesia and undergo wound cleansing and dressing of all wounds with&#xD;
      antibacterial solutions. Following wound cleansing and antibacterial treatments, subjects&#xD;
      will undergo the eschar removal process as per treatment assignment (NexoBrid or SOC,&#xD;
      following randomization). Subsequent to eschar removal, all wounds will be assessed and&#xD;
      treated in the same manner, in accordance with post-eschar removal wound care strategy.&#xD;
      Furthermore, subjects will undergo daily assessments (Vital signs (VS) and pain assessments)&#xD;
      for one week and weekly assessments thereafter, until wound closure. Following wound closure,&#xD;
      subjects will be followed up at 6 weeks, 12 weeks, and after that, at 6, 12, 18 and 24 months&#xD;
      (for a blinded assessment of cosmesis, function and QoL evaluation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Earlier eschar removal (in days)</measure>
    <time_frame>participants will be followed from randomization date and daily for the duration of hospital stay, an expected average of 3 weeks</time_frame>
    <description>Demonstrate superiority over SOC for eschar removal as measured by a survival analysis of incidence of complete eschar removal as a function of time. Eschar removal will be measured at the end of the debridement starting from randomization date.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Thermal Burns</condition>
  <arm_group>
    <arm_group_label>NexoBrid Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NexoBrid Gel is applied to the burn wound at a dose of 2g or 5g NexoBrid sterile powder mixed with 20g or 50g sterile Gel Vehicle per 180cm^2 of TBSA for four hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non surgical and Surgical Debridement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NexoBrid</intervention_name>
    <description>NexoBrid is an enzymatic debriding agent for Eschar Removal.</description>
    <arm_group_label>NexoBrid Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Surgical or Non-Surgical methods for Eschar Removal</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Stage 1: Males and females between 4 years to 18 years of age, Stage 2 (upon DSMB&#xD;
             review): Males and females between 1 year to 18 years of age, Stage 3 (upon DSMB&#xD;
             review): Males and females between 0 years to 18 years of age.&#xD;
&#xD;
          2. Thermal burns caused by fire/flame, scalds or contact.&#xD;
&#xD;
          3. Patient total burns area ≥ 1% DPT and / or FT,&#xD;
&#xD;
          4. Patient total burns area should be ≤ 30% TBSA; SPT, DPT and/or FT in depth,&#xD;
&#xD;
          5. Signed written informed consent by a legal guardian can be obtained within 84 hours of&#xD;
             the burn injury.&#xD;
&#xD;
        At least one wound (a continuous burn area which can be treated in one session; might&#xD;
        include several anatomical areas) in a patient should meet all following criteria:&#xD;
&#xD;
          1. Wound that is ≥ 1% TBSA (DPT and/or FT) (not including face, perineal or genital),&#xD;
&#xD;
          2. Wound is composed of DPT and/or FT in depth. Superficial partial thickness areas may&#xD;
             be included in the wound area only if cannot be separated from deeper areas (e.g.&#xD;
             surrounded by or mixed with DPT areas) and might interfere with the treatment of the&#xD;
             deeper areas,&#xD;
&#xD;
          3. Wound that is potentially intended for surgical eschar removal,&#xD;
&#xD;
          4. Wound's blisters can be unroofed, as judged by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients weighing less than 3kg,&#xD;
&#xD;
          2. Patients who are unable to follow study procedures and follow up period,&#xD;
&#xD;
          3. Patients with electrical or chemical burns,&#xD;
&#xD;
          4. Patient with a continuous burn area above 15% TBSA,&#xD;
&#xD;
          5. Patients with no DPT and/or FT burn area (only SPT wounds),&#xD;
&#xD;
          6. Patient with circumferential anterior/posterior trunk fire/flame burns, &gt;15% TBSA&#xD;
             (Circumferential is defined as encircling ≥ 80% of the trunk circumference),&#xD;
&#xD;
          7. The following pre-enrolment dressings: a. Flammacerium, b. Silver Nitrate (AgNO3),&#xD;
&#xD;
          8. Patients with diagnosed infections,&#xD;
&#xD;
          9. Diagnosis of smoke inhalation injury,&#xD;
&#xD;
         10. Patients with pre-enrolment wounds which are covered by eschar saturated with iodine&#xD;
             or by SSD pseudoeschar (e.g. pseudoeschar as a result of &gt;12h SSD treatment),&#xD;
&#xD;
         11. Patients with pre-enrolment escharotomy,&#xD;
&#xD;
         12. Pregnant women (positive pregnancy test) or nursing mothers,&#xD;
&#xD;
         13. Poorly controlled diabetes mellitus (HbA1c&gt;9%),&#xD;
&#xD;
         14. Known Cardio-pulmonary disease, oxygen-dependent pulmonary diseases,&#xD;
             broncho-pneumonia, uncontrolled asthma,&#xD;
&#xD;
         15. Known conditions which interfere with circulation (peripheral vascular disease, edema,&#xD;
             lymphedema, surgery to the regional lymph nodes, obesity),&#xD;
&#xD;
         16. Any known conditions that would preclude safe participation in the study or adding&#xD;
             further risk to the basic acute burn trauma (such as immuno-compromising diseases,&#xD;
             life threatening trauma, severe pre-existing coagulation disorder,&#xD;
             pulmono-cardiovascular, liver or neoplastic disease),&#xD;
&#xD;
         17. ASA greater than 2&#xD;
&#xD;
         18. Chronic systemic steroid intake,&#xD;
&#xD;
         19. History of allergy and/or known sensitivity to pineapples, papaya, Bromelain or&#xD;
             papain,&#xD;
&#xD;
         20. Current (within 12 months prior to screening) suicide attempt,&#xD;
&#xD;
         21. Enrollment in any investigational drug trial within 4 weeks prior to screening,&#xD;
&#xD;
         22. Current (within 12 months prior to screening) alcohol (daily consumption &gt; 3 units for&#xD;
             males and &gt;2 units for females) or drug abuse,&#xD;
&#xD;
         23. Prisoners and incarcerated&#xD;
&#xD;
         24. Patients who might depend on the clinical study site or investigator.&#xD;
&#xD;
         25. Patient expresses objection to participate in the study.&#xD;
&#xD;
         26. Patients with other severe cutaneous trauma at the same sites as the burns (i.e.&#xD;
             blunt, avulsion or deep abrasion) or previous burn(s) at the same treatment site(s)&#xD;
&#xD;
         27. General condition of patient would contraindicate surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lior Rosenberg, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>MediWound Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yaron Shoham, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>MediWound Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maricopa Special Health Care District</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of South Florida Board of Trustees</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Hospital &amp; Health Center dba Legacy Research Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shawn Jekins Children's Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425s</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Plastic Surgery</name>
      <address>
        <city>Gent</city>
        <zip>B 9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Khechinashvili University Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin Zentrum für Schwerbrandverletzte mit Plastischer Chirurgie</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart - Olgahospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MRE Bethesda Gyermekkórháza</name>
      <address>
        <city>Budapest</city>
        <zip>H-1146</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B.A.Z Megyei Kórház és Egyetemi Oktatókórház</name>
      <address>
        <city>Miskolc</city>
        <zip>H-3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikai Kozpont Gyermekgyogyaszati Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Ram Manohar Lohia Hospital, Baba Kharak Singh Marg</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krishna Rajendra Hospital</name>
      <address>
        <city>Mysuru</city>
        <zip>570001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vardhman Mahavir Medical College (VLCC) and Safdarjung Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitary Integrated Hospital Verona (AOUI Verona),</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acute Burn Care &amp;Trauma Surgery, Dept Surgery/Burn Center, Rode Kruis Ziekenhuis, LUMC University Leiden</name>
      <address>
        <city>Beverwijk</city>
        <zip>1942</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Dzieciecy w Krakowie</name>
      <address>
        <city>Kraków</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Dzieciecy im.prof.dr.med Jana Bogdanowicza, Oddzial Chirurgii i Urologii Dzieciecej z Pododdzialem Leczenia Oparzen</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii &quot;Sfanta Maria&quot;</name>
      <address>
        <city>Iasi</city>
        <zip>700309</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta Tg- Mures</name>
      <address>
        <city>Târgu-Mureş</city>
        <zip>54000</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitná nemocnica Bratislava, Klinika popálenin a rekonštrukčnej chirurgie</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Paz University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulevar Sur s/n</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNPE &quot;City clinical hospital of immediate and urgent medical aid n.a.Meshchaninov&quot; of Kharkiv CC and State institution 'Zaitsev V.T. Institute of general and urgent surgery of the National academy of medical sciences of Ukraine'</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal institution &quot;Odessa Regional Clinical Medical Center&quot;</name>
      <address>
        <city>Odesa</city>
        <zip>65049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children´s Hospital NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Israel</country>
    <country>Sweden</country>
  </removed_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=nexobrid</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Rosenberg L, Krieger Y, Bogdanov-Berezovski A, Silberstein E, Shoham Y, Singer AJ. A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT. Burns. 2014 May;40(3):466-74. doi: 10.1016/j.burns.2013.08.013. Epub 2013 Sep 26.</citation>
    <PMID>24074719</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

